← Back to Search

Monoclonal Antibodies

Bimekizumab for Ankylosing Spondylitis (BE MOVING Trial)

Phase 3
Waitlist Available
Research Sponsored by UCB Biopharma SRL
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Must not have
Female study participants who plan to become pregnant during the study or within 20 weeks following final dose of Investigational Medicinal Product (IMP)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from baseline of as0010 (nct03928704) or as0011 (nct03928743) to week 112
Awards & highlights
No Placebo-Only Group
Pivotal Trial

Summary

This trial is testing a medication called bimekizumab to see if it is safe and effective for people with a type of chronic back and joint inflammation called axial spondyloarthritis, which includes ankylosing spondylitis. The medication works by blocking proteins that cause inflammation, helping to reduce pain and swelling. Bimekizumab has shown promising results in previous studies for conditions like psoriatic arthritis and ankylosing spondylitis.

Who is the study for?
This trial is for people with active axial spondyloarthritis, including ankylosing spondylitis and nonradiographic forms. Participants must have completed previous related studies (AS0010 or AS0011), be reliable in following the study protocol, and are expected to benefit from it. Those with ongoing serious adverse events, serious infections history, or positive IGRA tests need medical consultation before joining.
What is being tested?
The trial is testing Bimekizumab's long-term safety, tolerability, and effectiveness in treating axial spondyloarthritis conditions like ankylosing spondylitis. It aims to show how well patients do over a longer period while taking this medication.
What are the potential side effects?
While not specified here, Bimekizumab may cause side effects such as injection site reactions, infections due to immune system suppression, allergic reactions, gastrointestinal issues among others based on its mechanism of action.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I do not plan to become pregnant during the study or within 5 months after the last dose.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline of as0010 (nct03928704) or as0011 (nct03928743) to week 112
This trial's timeline: 3 weeks for screening, Varies for treatment, and from baseline of as0010 (nct03928704) or as0011 (nct03928743) to week 112 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Percentage of participants with serious adverse events (SAEs) during the study
Percentage of participants with treatment-emergent adverse events (TEAEs) during the study
Percentage of participants with with treatment-emergent adverse Events (TEAEs) leading to withdrawal from the study
Secondary study objectives
Assessment of Ankylosing Spondylitis Disease Activity Score-C-reactive protein (ASDAS-CRP) at Week 112
Assessment of Ankylosing Spondylitis Disease Activity Score-C-reactive protein (ASDAS-CRP) at Week 28
Assessment of Ankylosing Spondylitis Disease Activity Score-C-reactive protein (ASDAS-CRP) at Week 52
+33 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

1Treatment groups
Experimental Treatment
Group I: BimekizumabExperimental Treatment1 Intervention
Subjects will receive bimekizumab throughout the Treatment Period.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Bimekizumab
2018
Completed Phase 3
~6500

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Ankylosing Spondylitis (AS) target specific cytokines involved in the inflammatory process. Bimekizumab, for example, inhibits both Interleukin-17A (IL-17A) and Interleukin-17F (IL-17F), which are key drivers of inflammation and new bone formation in AS. By blocking these cytokines, Bimekizumab can reduce inflammation and prevent structural damage to the spine and sacroiliac joints. Similarly, TNF inhibitors, another common treatment, block Tumor Necrosis Factor-alpha (TNF-alpha), a cytokine that promotes inflammation and joint damage. These treatments are crucial for AS patients as they help manage symptoms, maintain function, and prevent long-term complications.
Targeting the Interleukin-23/Interleukin-17 Inflammatory Pathway: Successes and Failures in the Treatment of Axial Spondyloarthritis.Treating to target in axial spondyloarthritis: defining the target and the arrow.

Find a Location

Who is running the clinical trial?

UCB Biopharma SRLLead Sponsor
115 Previous Clinical Trials
22,398 Total Patients Enrolled
UCB CaresStudy Director001 844 599 2273 (UCB)
219 Previous Clinical Trials
45,772 Total Patients Enrolled

Media Library

Bimekizumab (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT04436640 — Phase 3
Ankylosing Spondylitis Research Study Groups: Bimekizumab
Ankylosing Spondylitis Clinical Trial 2023: Bimekizumab Highlights & Side Effects. Trial Name: NCT04436640 — Phase 3
Bimekizumab (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04436640 — Phase 3
Ankylosing Spondylitis Patient Testimony for trial: Trial Name: NCT04436640 — Phase 3
~132 spots leftby Aug 2026